secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001829126-25-007323
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc receives FDA authorization to proceed with Phase II clinical trial of NEO212 for brain cancer
--------------------------------------------------------------------------------

- FDA cleared NEO212-01 Phase IIa/IIb after Phase I showed safe dosing up to 810 mg daily days 1–5 of 28-day cycle.
- Patient enrollment expected to begin before end of 2025 at up to 16 U.S. cancer centers including Cleveland Clinic, Duke, and USC.
- NEO212 is an oral chemical conjugate of TMZ (Temodar) and NEO100 (perillyl alcohol), designed to enhance blood-brain barrier penetration.
- Company believes NEO212 could replace TMZ as standard of care for glioblastoma, astrocytoma, and other CNS cancers.
- CEO Dr. Thomas Chen and Executive Chairman Amir Heshmatpour highlighted milestone as transformative for brain cancer treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625007323/0001829126-25-007323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625007323/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-007323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer